REFERENCES
1. Gross S, Keefer V, Newman AJ. The Platelets in Iron-Deficiency
Anemia. I. The Response to Oral and Parenteral Iron. Pediatrics
1964;34:315-23.
2. Wang JL, Huang LT, Wu KH, Lin HW, Ho MY, Liu HE. Associations of
reactive thrombocytosis with clinical characteristics in pediatric
diseases. Pediatr Neonatol 2011;52:261-6.
3. Nelson ND, Marcogliese A, Bergstrom K, Scheurer M, Mahoney D, Bertuch
AA. Thrombopoietin Measurement as a Key Component in the Evaluation of
Pediatric Thrombocytosis. Pediatr Blood Cancer 2016;63:1484-7.
4. Kucine N, Viny AD, Rampal R, et al. Genetic analysis of five children
with essential thrombocytosis identified mutations in cancer-associated
genes with roles in transcriptional regulation. Haematologica
2016;101:e237-9.
5. Westwick J, Watson-Williams EJ, Krishnamurthi S, et al. Platelet
activation during steady state sickle cell disease. J Med 1983;14:17-36.
6. Eder AF, Yau YY, West K. The effect of iron balance on platelet
counts in blood donors. Transfusion 2017;57:304-12.
7. Ganti AK, Moazzam N, Laroia S, Tendulkar K, Potti A, Mehdi SA.
Predictive value of absent bone marrow iron stores in the clinical
diagnosis of iron deficiency anemia. In Vivo 2003;17:389-92.
8. Rumi E, Pietra D, Ferretti V, et al. JAK2 or CALR mutation status
defines subtypes of essential thrombocythemia with substantially
different clinical course and outcomes. Blood 2014;123:1544-51.
9. Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in
myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med
2013;369:2391-405.
10. Tefferi A, Lasho TL, Abdel-Wahab O, et al. IDH1 and IDH2 mutation
studies in 1473 patients with chronic-, fibrotic- or blast-phase
essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia
2010;24:1302-9.
11. McNamara CJ, Panzarella T, Kennedy JA, et al. The mutational
landscape of accelerated- and blast-phase myeloproliferative neoplasms
impacts patient outcomes. Blood Adv 2018;2:2658-71.
12. Lin CC, Hou HA, Chou WC, et al. SF3B1 mutations in patients with
myelodysplastic syndromes: the mutation is stable during disease
evolution. Am J Hematol 2014;89:E109-15.
13. McClure RF, Ewalt MD, Crow J, et al. Clinical Significance of DNA
Variants in Chronic Myeloid Neoplasms: A Report of the Association for
Molecular Pathology. J Mol Diagn 2018;20:717-37.
14. Kondo T, Okabe M, Sanada M, et al. Familial essential
thrombocythemia associated with one-base deletion in the 5’-untranslated
region of the thrombopoietin gene. Blood 1998;92:1091-6.
15. Budde U, van Genderen PJ. Acquired von Willebrand disease in
patients with high platelet counts. Semin Thromb Hemost 1997;23:425-31.
16. Lancellotti S, Dragani A, Ranalli P, et al. Qualitative and
quantitative modifications of von Willebrand factor in patients with
essential thrombocythemia and controlled platelet count. J Thromb
Haemost 2015;13:1226-37.
17. Bodo I, Eikenboom J, Montgomery R, et al. Platelet-dependent von
Willebrand factor activity. Nomenclature and methodology: communication
from the SSC of the ISTH. J Thromb Haemost 2015;13:1345-50.
18. Flood VH, Gill JC, Morateck PA, et al. Common VWF exon 28
polymorphisms in African Americans affecting the VWF activity assay by
ristocetin cofactor. Blood 2010;116:280-6.
19. The Diagnosis, Evaluation, and Management of von Willebrand
Disease2007 December 2007. Report No.: NIH Publication No. 08-5832.
20. Nichols WL, Hultin MB, James AH, et al. von Willebrand disease
(VWD): evidence-based diagnosis and management guidelines, the National
Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA).
Haemophilia 2008;14:171-232.